Who Paid My Doc
Lisa Brailey
Clinical Molecular Genetics Shelton, CT Medical Doctor
NPI 1285776708 CMS profile 400374
1 Forest Pkwy, Dianon Systems, Shelton, CT 06484
General payments
$25
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$245,674
Through program year 2023, Lisa Brailey of Shelton, CT is reported in the CMS Open Payments database as having received $25 across 1 general payment and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $245,674 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
By program year
1 row| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2023 | General | $25 | 1 |
Beside peers
- Lisa Brailey
- Connecticut median
- Middle half of Connecticut
- National median
In program year 2025, general payments to Lisa Brailey were reported at $0. Among 12,665 Connecticut profiles paid that year, the median was $167 and the middle half received between $54 and $639.
Show as a table
| Year | Lisa Brailey | Connecticut median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $163 | $50–$671 | $163 |
| 2020 | $0 | $111 | $33–$382 | $114 |
| 2021 | $0 | $124 | $39–$443 | $132 |
| 2022 | $0 | $138 | $45–$535 | $149 |
| 2023 | $25 | $148 | $47–$556 | $160 |
| 2024 | $0 | $157 | $49–$599 | $164 |
| 2025 | $0 | $167 | $54–$639 | $169 |
Breakdown
Billing to Medicare
Part B · data year 2024 · 3 billing codesPaid by Medicare
$16,558
Medicare patients
105
Services billed
112
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| Cancer | 75% | |
| High blood pressure | 73% | |
| Arthritis | 44% | |
| Diabetes | 35% | |
| Osteoporosis | 30% | |
| Ischemic heart disease | 25% | |
| Chronic kidney disease | 20% | |
| Atrial fibrillation | 17% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
1 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
Clinical Molecular Genetics in Connecticut
Practitioners in the same specialty and state, ranked by reported value.
All Clinical Molecular Genetics
Everyone recorded under this specialty, nationwide.
Doctors in Connecticut
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.